Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1994 Nov;85(11):1159–1164. doi: 10.1111/j.1349-7006.1994.tb02922.x

Potentiation of cis‐Diammine(1, 1‐cyclobutanedicarboxylato)platinum(II) by Amphotericin B in BALB/c Nude Mice Bearing Human Ovarian Carcinoma Cells

Masayoshi Kojima 1, Fumitaka Kikkawa 1,✉, Hidenori Oguchi 1, Koji Tamakoshi 1, Osamu Maeda 1, Nobuhiko Suganuma 1, Yutaka Tomoda 1
PMCID: PMC5919377  PMID: 7829402

Abstract

Human ovarian carcinoma cells (HRA) were sensitized to cis‐diammine(l, l‐cyclobutanedicarboxylato)platinum(II) (CBDCA) 1.2‐, 2.1‐ and 3.4‐fold by treatment with amphotericin B (AMB) at concentrations of 2.1, 5.4, and 10.8 μM, respectively. Moreover, the intracellular accumulation of platinum after 2‐h exposure to CBDCA was increased significantly by AMB treatment. For estimating the enhancing effect of AMB on CBDCA cytotoxicity in vivo, we prepared HRA cell‐inoculated nude mice. Ascites was evident 7 to 9 days after intraperitoneal (i.p.) inoculation of HRA cells, and the mice died of intraabdominal carcinomatosis 11 to 14 days (mean survival time (MST): 12.0±1.0 days) after inoculation. Treatment with AMB (2.0 mg/kg) alone increased the MST by only 1.2 days. Simultaneous treatment with CBDCA (12 or 15 mg/kg) and AMB (0.5 to 2.0 mg/kg) produced a significant increase in MST compared to treatment with CBDCA alone. Maximal MST (38.5 days) was obtained by treatment with 15 mgAg CBDCA plus 2.0 mg/kg AMB, whereas the MST with 15 mg/kg CBDCA alone was 15.8 days. A drug accumulation study demonstrated that platinum accumulation in tumor tissues after i.p. treatment with CBDCA and AMB in tumor‐bearing nude mice was increased significantly compared to treatment with CBDCA alone. These findings indicate that intraperitoneal combination chemotherapy with CBDCA and AMB is useful in nude mice with advanced ovarian carcinoma.

Keywords: CBDCA, Ovarian carcinoma, Biochemical modulation, Amphotericin B, Intraperitoneal chemotherapy

Full Text

The Full Text of this article is available as a PDF (370.6 KB).

REFERENCES

  • 1. ) Canetta , R. , Rozenewieg , M. and Carter , S. K.Carboplatin: the clinical spectrum to date . Cancer Treat, Rev. , 12 , 125 – 130 ( 1985. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Canetta , R. , Bragman , K. , Smaldone , L. and Rozeneweig , M.Carboplatin: current status and future prospects . Cancer Treat. Rev. , 15 , 17 – 31 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Malmstrom , H. , Larssona D , and Simonsen , E.Phase I study of intraperitoneal carboplatin as adjuvant therapy in early ovarian cancer . Gynecol. Oncol. , 39 , 289 – 294 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Speyer , J. L. , Seller , U. , Colombo , N. , Sorich , J. , Werns , J. C. , Hochster , H. , Green , M. , Forges , R. , Muggia , F. M. , Canetta , R. and Beckman , M.Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy . J. Clin. Oncol. , 8 , 1335 – 1341 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Conte , P. F. , Bruzzone , M. and Carnino , F.Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III‐IV epithelial ovarian carcinoma . J. Clin. Oncol. , 9 , 658 – 663 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Markman , M. , Reichman , B. , Hakes , T. , Rubin , S. , Jones , W. , Lewis , J. L. , Barakat , R. , Curtin , J. , Almadrones , L. and Hoskins , W.Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelian ovarian cancer . Gynecol. Oncol. , 47 , 353 – 357 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Hansson , J. , Edgren , M. , Ehrsson , H. , Ringborg , U. and Nilsson , B.Effects of D, L‐buthionine‐S, R‐sulfoximine on cytotoxicity and DNA cross‐linking induced by bifunctional DNA‐reactive cytostatic drug in human melanoma cells . Cancer Res. , 48 , 19 – 26 ( 1988. ). [PubMed] [Google Scholar]
  • 8. ) Chen , G. and Zeller , W. J.Enhancement of cisplatin (DDP) antitumor activity by 3‐aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo . Cancer Chemother. Pharmacol , 26 , 37 – 41 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Silverstrini , R. , Zaffaroni , N. , Villa , R. , Crlandi , L. and Costa , A.Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells . Int. J. Cancer , 52 , 813 – 817 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Hamilton‐Miller , J. M. T.Chemistry and biology of the polyene macrolide antibiotics . Bacterial. Rev. , 37 , 166 – 196 ( 1973. ). [PMC free article] [PubMed] [Google Scholar]
  • 11. ) Sutton , D. D. , Arnow , P. M. and Lampen , J. O.Effects of high concentrations of nystatin upon glycolysis and cellular permeability in yeast . Soc. Exp. Biol. Med. , 108 , 107 – 175 ( 1961. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Zygmunt , W. A.Intracellular loss of potassium in Candida albicans after exposure to polyene antifungal antibiotics . Appl. Microbiol , 14 , 953 – 956 ( 1966. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. ) Morikage , T. , Ohmori , T. , Nishio , K. , Fujiwara , Y. , Takeda , Y. and Saijo , N.Modulation of cisplatin sensitivity and accumulation by ampbotericin B in cisplatin‐resistant human lung cancer cell lines . Cancer Res. , 53 , 3302 – 3307 ( 1993. ). [PubMed] [Google Scholar]
  • 14. ) Kikkawa , F. , Kojima , M. , Oguchi , H. , Maeda , O. , Ishikawa , H. , Tamakoshi , K. , Mizuno , K. , Kawai , M. , Suganuma , N. and Tomoda , Y.Potentiating effect of amphotericin B on five platinum anticancer drugs in human cis‐diamrninedichloroplatinum(II) sensitive and resistant ovarian carcinoma cells . Anticancer Res. , 13 , 891 – 896 ( 1993. ). [PubMed] [Google Scholar]
  • 15. ) Kiessel , D.Alteration of cell permeability barriers by amphotericin B‐deoxydiolate (Fungizone) in vitro . Biochem. Pharmacol. , 25 , 483 – 485 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Medoff , G. , Valeriote , F. , Lynch , R. G. , Schlessinger , D. and Kobayashi , G. S.Synergistic effect of amphotericin B and l,3‐bis(2‐chloroethyl)‐l‐nitrosourea against a transplantable AKR leukemia . Cancer Res. , 34 , 974 – 978 ( 1974. ). [PubMed] [Google Scholar]
  • 17. ) Medoff , G. , Valeriote , F. , Ryan , J. and Tolen , S.Response of transplanted AKR leukemia to combination therapy with amphotericin B and 1,3‐bis(2‐chloroethyl)‐l‐nitrosourea: dose and schedule dependency . J. Natl. Cancer Inst. , 58 , 949 – 953 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 18. ) Medoff , G. , Valeriote , F. and Dieckman , J.Potentiation of anticancer agents by amphotericin B . J. Natl. Cancer Inst. , 61 , 131 – 135 ( 1981. ). [PubMed] [Google Scholar]
  • 19. ) Presant , C. A. , Klahr , C. , Olander , J. and Gatewood , D.Amphotericin B plus 1,3‐bis(2‐chloroethyl)‐l‐nitrosourea (BCNU‐NSC No. 409962) in advanced cancer . Cancer , 38 , 1917 – 1921 ( 1976. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Presant , C. A. , Klahr , C. and Santala , R.Amphotericin B induction of sensitivity to adriamycin, 1,3‐bis(2‐chloro‐ethyl)‐l‐nitrosourea (BCNU) plus cyclophosphamide in human neoplasia . Ann. Intern. Med. , 86 , 47 – 51 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Presant , C. A. , Hillingwe , S. and Klahr , C.Phase II study of 1,3‐bis(2‐chloroethyl)‐l‐nitrosourea (BCNU, NSC #409962) with amphotericin B in bronchogenic carcinoma . Cancer , 45 , 6 – 10 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Ozols , R. F. , Young , R. C. , Speyer , J. L. , Sugarbaker , P. H. , Green , R. , Jenkins , J. and Myers , C. E.Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer . Cancer Res. , 42 , 4265 – 4269 ( 1982. ). [PubMed] [Google Scholar]
  • 23. ) Speyer , J. L. and Sorich , J.Intraperitoneal carboplatin: rationale and experience . J. Clin. Oncol , 19 , 107 – 113 ( 1992. ). [PubMed] [Google Scholar]
  • 24. ) Howell , S. B. , Zimm , S. , Markman , M. , Abramson , I. S. , Clearly , S. , Lucas , W. E. and Weiss , R. J.Long‐term survival of advanced refractory ovarian carcinoma patients with small‐volume disease treated with Intraperitoneal chemotherapy . J Clin. Oncol , 5 , 1607 – 1612 ( 1987. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Repett , L. S. , Chiarah , S. T. , Guido , T. M. , Bruzzone , M. , Oliva , C. , Ragni , N. , Conte , P. F. and Rosso , R.Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study . Anticancer Res. , 11 , 1641 – 1644 ( 1991. ). [PubMed] [Google Scholar]
  • 26. ) Mizuno , K. , Furuhashi , Y. , Maeda , O. , Iwata , M. , Misawa , T. , Kawai , M. , Kano , T. and Tomoda , Y.Mitomycin C cross‐resistance induced by adriamycin in human ovarian cancer cells in vitro . Cancer Chetnother. Pharmacol. , 26 , 333 – 339 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 27. ) Pera , M. F. and Harder , H. C.Analysis for platinum in biological material by flameless atomic absorption spectrometry . Clin. Chem. , 23 , 1245 – 1249 ( 1977. ). [PubMed] [Google Scholar]
  • 28. ) Medoff , J. , Medoff , G. , Goldstein , M. N. , Schlessinger , D. and Kobayashi , G. S.Amphotericin B‐induced sensitivity to actinomycin D in drug‐resistant HeLa cells . Cancer Res. , 35 , 2548 – 2552 ( 1975. ). [PubMed] [Google Scholar]
  • 29. ) Presant , C. A. and Carr , D.Amphotericin B (Fungizone) enhancement of nitrogen mustard uptake by human tumor cells . Biochem. Biophys. Res. Commim. , 93 , 1063 – 1073 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 30. ) Krishan , A. , Sauertei , A. and Gordon , K.Effects of amphotericin B on adriamycin transport in P388 cells . Cancer Res. , 45 , 4097 – 4102 ( 1985. ). [PubMed] [Google Scholar]
  • 31. ) Ozole , R. F. , Hogen , W. M. , Grotsinger , K. R. , McCoy , W. and Young , R. C.Effects of amphotericin B on adriamycin and melphalan cytotoxicity in human and murine ovarian carcinoma and in L1210 leukemia . Cancer Res. , 43 , 959 – 964 ( 1983. ). [PubMed] [Google Scholar]
  • 32. ) Peter , S. R. , Patrick , W. D. , Joseph , L. W. and Marilyn , B.Treatment of torulopsis glabrata peritonitis with intra‐peritoneal amphotericin B . J. Am. Med. Assoc. , 9 , 1187 – 1189 ( 1983. ). [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES